Human leukocyte antigen class I alleles can predict response to pegylated interferon/ribavirin therapy in chronic hepatitis C Egyptian patients

Archives of Iranian Medicine

Volumn 16, Issue 2, 2013, Pages 68-73

  Farag, Raghda E ^a   Arafa, Mona M ^a   El Etreby, Shahira ^a   Saudy, Niveen S ^a   Eldeek, Basem S ^b   El Alfy, Hatem A ^a   Goda, Inas F ^a   Ali, Rabab M ^a  

^a MANSOURA UNIVERSITY   (Egypt)

^b KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

Author keywords

Fibrosis; HCV; HLA alleles; Peg IFN Ribavirin therapy; Treatment response

Indexed keywords

HLA A1 ANTIGEN; HLA ANTIGEN CLASS 1; HLA B38 ANTIGEN; PEGINTERFERON ALPHA2A PLUS RIBAVIRIN; VIRUS RNA;

ADULT; ALLELE; ARTICLE; CHRONIC HEPATITIS; CONTROLLED STUDY; DRUG TREATMENT FAILURE; EGYPTIAN; ETHNIC GROUP; FATTY LIVER; FEMALE; GENE; GENE FREQUENCY; GENOTYPE; HEPATITIS C; HLA A01 GENE; HLA B38 GENE; HUMAN; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; SEROLOGY; TREATMENT DURATION; TREATMENT RESPONSE; VIRAL CLEARANCE; VIREMIA; VIRUS LOAD;

ADULT; ALLELES; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; EGYPT; FEMALE; GENES, MHC CLASS I; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; MALE; MIDDLE AGED; RIBAVIRIN; TREATMENT OUTCOME;

EID: 84874353739     PISSN: 10292977     EISSN: 17353947     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis. 2005; 5: 558 - 567.
2. Manns MP, Foster GR, Rockstroh JK, Zeuzem S, Zoulim F, Houghton M. The way forward in HCV treatment - finding the right path. Nat Rev Drug Discov. 2007; 6: 991 - 1000.
3. Pawlotsky JM, Chevaliez S, McHutchison JG. The hepatitis C virus life cycle as a target for new antiviral therapies. Gastroenterology. 2007; 132: 1979 - 1998.
4. Maekawa S, Enomoto N. Viral factors influencing the response to the combination therapy of peginterferon plus ribavirin in chronic hepatitis C. J Gastroenterol. 2009; 44: 1009 - 1015.
5. Rhodes SL, Erlich H, Im KA, Wang J, Li J, Bugawan T, et al. Association between the Human MHC and sustained virological response in treatment of chronic hepatitis C virus infection. Genes Immun. 2008; 9: 328 - 333.
6. Singh R, Kaul R, Kaul A, Khan KA. Comparative review of HLA association with hepatits B and C viral infections across global populations. World J Gasterol. 2007; 13: 1770 - 1787.
7. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, et al. Histological grading and staging of chronic hepatitis. J Hepatol. 1995; 22: 696 - 699.
8. Ohno O, Mizokami M, Wu RR, Saleh MG, Ohba K, Orito E, et al. New hepatitis C virus (HCV) genotyping system that allows for identification of HCV genotypes 1a, 1b, 2a, 2b, 3a, 3b, 4, 5a, and 6a. J Clin Microbiol. 1997; 35: 201 - 207.
9. Terasaki PI, Park MS. Microdroplet lymphocyte cytotoxicity test. In: Ray JG, ed. Manual of Tissue Typing Techniques. Bethesda: NIH; 1980: 92 - 103.
10. Dai CY, Chuang WL, Hsieh MY, Huang JF, Lin YY, Chu PY, et al. Human leukocyte antigen alleles and the response to pegylated interferon/ribavirin therapy in chronic hepatitis C patients. Antiviral Res. 2010; 85: 396 - 402.
11. Kikuchi I, Ueda A, Mihara K, Miyanaga O, Machidori H, Ishikawa E, et al. The effect of HLA alleles on response to Interferon therapy in patients with chronic hepatitis C. Eur J Gastroenterol Hepatol. 1998; 10: 859 - 863.
12. Miyaguchi S, Saito H, Ebinuma H, Morizane T, Ishii H. Possible association between HLA antigens and the response to interferon in Japanese Patients with chronic hepatitis C. Tissue Antigens. 1997; 49: 605 - 611.
13. Nishiguchi S, Kaneshiro S, Tanaka M, Enomoto M, Akihiro T, Habu D, et al. Association of HLA alleles with response (especially biochemical response) to interferon therapy in Japanese patients with chronic hepatitis C. J Interferon Cytokine Res. 2003; 23: 135 - 141.
14. Romero-Gómez M, González-Escribano MF, Torres B, Barroso N, Montes-Cano MA, Sánchez-Muñoz D, et al. HLA class I B44 is as-- sociated with sustained response to interferon + ribavirin therapy in patients with chronic hepatitis C. Am J Gastroenterol. 2003; 98: 1621 - 1626.
15. Dinçer D, Besisik F, Oǧuz F, Sever MS, Kaymakoglu S, Cakaloglu Y, et al. Genes of major histocompatibility complex class II influence chronic C hepatitis treatment with interferon in hemodialysis patients. Int J Artif Organs. 2001; 24: 212 - 214.
16. Yu ML, Dai CY, Chen SC, Chiu CC, Lee LP, Lin ZY, et al. Human leukocyte antigen class I and II alleles and response to interferon-alpha treatment in Taiwanese patients with chronic hepatitis C virus infection. J Infect Dis. 2003; 188: 62 - 65.
17. Lau JY, Tam RC, Liang TJ, Hong Z. Mechanism of action of ribavirin in the combination treatment of chronic HCV infection. Hepatology. 2002; 35: 1002 - 1009.
18. Almarri A, El Dwick N, Al Kabi S, Sleem K, Rashed A, Ritter MA, et al. Interferon-alpha therapy in HCV hepatitis: HLA phenotype and cirrhosis are independent predictors of clinical outcome. Hum Immunol. 1998; 59: 239 - 242.
19. Heathcote EJ, Shiffman ML, Cooksley WG, Dusheiko GM, Lee SS, Balart L, et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N England J Med. 2000; 343: 1673 - 1680.
20. Dufour JF, DeLellis R, Kaplan MM. Regression of hepatic fibrosis in hepatitis C with long-term interferon treatment. Dig Dis Sci. 1998; 43: 2573 - 2576.
21. Arif A, Levine RA, Sanderson SO, Bank L, Velu RP, Shah A, et al. Regression of fibrosis in chronic hepatitis C treated with interferonbased therapy. Dig Dis Sci. 2003; 48: 1425 - 1430.
22. Hasan F, Asker H, Al-Khaldi J, Siddique I, Al-Ajmi M, Owaid S, et al. Peginterferon-alpha 2b plus ribavirin for the treatment of chronic hepatitis C genotype 4. Am J Gastroentrol. 2004; 99: 1733 - 1737.
23. Shiffman ML, Suter F, Bacon BR, Nelson D, Harley H, Solá R, et al. Peginterferon alfa2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med. 2007; 357: 124 - 134.
24. Zeuzem S, Hultcrantz R, Bourliere M, Goeser T, Marcellin P, Sanchez-Tapias J, et al. Peginterferon alfa2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotype 2 or 3. J Hepatol. 2004; 40: 993 - 999.
25. Poynard T, McHutchison J, Goodman Z, Ling MH, Albrecht J. Is an 'a la carte' combination interferon alfa 2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? The ALGOVIRC Project Group. Hepatology. 2000; 31: 211 - 218.
26. Jacobson IM, Brown RS Jr, Freilich B, Afdhal N, Kwo PY, Santoro J, et al. Peginterferon alfa 2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial. Hepatology. 2007; 46: 971 - 981.
27. Poynard T, Ratziu V, McHutchison J, Manns M, Goodman Z, Zeuzem S, et al. Effect of treatment with peginterferon or interferon alfa 2b and ribavirin on steatosis in patients infected with hepatitis C infection. Hepatology. 2003; 38: 75 - 85.
28. Martinot-Peignoux M, Marcellin P, Pouteau M, Castelnau C, Boyer N, Poliquin M, et al. Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C. Hepatology. 1995; 22 (4 Pt 1): 1050 - 1056.
29. Romero AI, Lagging M, Westin J, Dhillon AP, Dustin LB, Pawlotsky JM, et al. Interferon (IFN)-gamma-inducible protein-10: association with histological results, viral kinetics, and outcome during treatment with pegylated IFN-alpha 2a and ribavirin for chronic hepatitis C virus infection. J Infect Dis. 2006; 194: 895 - 903.
30. Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004; 140: 346 - 355.
31. Zeuzem S. Heterogeneous virologic response rates to interferon-based therapy in patients with chronic hepatitis C: who responds less well? Ann Intern Med. 2004; 140: 370 - 381.
32. Berg T, von Wagner M, Nasser S, Sarrazin C, Heintges T, Gerlach T, et al. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of Peginterferon-alpha2a plus ribavirin. Gasteroentrology. 2006; 131: 1086 - 1097.
33. Zeuzem S, Buti M, Ferenci P, Sperl J, Horsmans Y, Cianciara J, et al. Effecacy of 24 weeks treatment with Peginterferon-alpha2a plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol. 2006; 44: 97 - 103.
34. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, et al. Randomised trial of interferon-alpha2a plus ribavirin for 48 weeks or for 24 weeks versus interferon-alpha2a plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet. 1998; 352: 1426 - 1432.